Skip to main content

Acalabrutinib Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 14, 2023.

Applies to acalabrutinib: oral tablet.

Serious side effects of Acalabrutinib

Along with its needed effects, acalabrutinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking acalabrutinib:

More common

Other side effects of Acalabrutinib

Some side effects of acalabrutinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to acalabrutinib: oral capsule, oral tablet.

General

The most common adverse reactions (reported incidence of 20% or greater) were anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, myalgia, and bruising.[Ref]

Cardiovascular

Very common (10% or more): Bleeding events (50%)

Common (1% to 10%): Hemorrhage/hematoma

Uncommon (0.1% to 1%): Atrial fibrillation, atrial flutter[Ref]

Hematologic

Very common (10% or more): Decreased hemoglobin (46%), decreased platelets (44%), decreased neutrophils (36%), neutropenia (23%), anemia (11%)

Common (1% to 10%): Thrombocytopenia[Ref]

Nervous system

Very common (10% or more): Headache (39%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (31%), nausea (19%), abdominal pain (15%), constipation (15%), vomiting (13%)[Ref]

Dermatologic

Very common (10% or more): Bruising/petechiae/ecchymosis/contusion (21%), rash (18%)[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (21%)[Ref]

Oncologic

Very common (10% or more): Second primary malignancies (11%)

Common (1% to 10%): Skin cancer[Ref]

Hepatic

Common (1% to 10%): Increased creatinine[Ref]

Respiratory

Common (1% to 10%): Epistaxis

Frequency not reported: Pneumonia[Ref]

Other

Very common (10% or more): Fatigue (28%)

Frequency not reported: Infections[Ref]

Frequently asked questions

References

1. Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.